Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropenia
| Autor: | Leszek Kraj, Joanna Krawczyk‑Lipiec, Grzegorz Orlik, Joanna Górniewska |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.medical_treatment Filgrastim Neutropenia General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Internal medicine Epidemiology medicine General Pharmacology Toxicology and Pharmaceutics Chemotherapy business.industry General Neuroscience Cancer Biosimilar General Medicine Articles medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis Immunology Absolute neutrophil count business Febrile neutropenia medicine.drug |
| Zdroj: | Biomedical reports. 7(2) |
| ISSN: | 2049-9434 |
| Popis: | Neutropenia and febrile neutropenia (FN) are among the most common side effects/complications of chemotherapy. The aim of the present study was to evaluate the practice of the use of biosimilar filgrastim in the primary and secondary prevention of FN, and assess its efficacy and safety. A multi-center, non-interventional epidemiological study of 170 cancer patients aged 23-82 years was conducted. Data were collected via a questionnaire completed based on medical documentation and patient examination over five chemotherapy visits. The risk of FN related to the chemotherapy protocol used was in the range of 10-20% in >50% of the patients (53.5%) and a majority (74.7%) had additional FN risk factors. 60% of the patients received filgrastim as primary prevention of FN, and 40% received it as secondary prevention. In 40.6% of cases, six cycles of chemotherapy were used. More than 90% of patients continued chemotherapy according to the initial recommended dose. In majority of patients, no FN was observed following the final cycle of chemotherapy. Median neutrophil count at visit 1 was 2.2×103/µl and did not fall below that level. Majority of patients (>70%) performed self-injections of filgrastim, and 86.3% of patients were continuing therapy with this drug at the last visit. No treatment-related side effects were recorded. The use of biosimilar filgrastim in the primary and secondary prevention of FN allows to maintain initial chemotherapy dosage. Furthermore, the use of biosimilar filgrastim is safe and tolerable, and has a high acceptance by patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|